Systematic Reviews and Meta-Analysis of Prognosis Studies (REVAMP): development of core methods, reporting guidelines and a methodology handbook

预后研究的系统评价和荟萃分析 (REVAMP):制定核心方法、报告指南和方法手册

基本信息

  • 批准号:
    MR/V038168/2
  • 负责人:
  • 金额:
    $ 47.74万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2023
  • 资助国家:
    英国
  • 起止时间:
    2023 至 无数据
  • 项目状态:
    未结题

项目摘要

Healthcare research is in an exciting new phase. Researchers now have access to large amounts of information to link an individual's characteristics (such as age, family history or genetic information) with health outcomes (such as death, pain level, depression score). Researchers are using this information to help health professionals and patients understand and predict future outcomes. Such research is called prognosis research, and covers four types: overall prognosis (what is the average outcome risk in a population?), prognostic factors (what characteristics of patients help understand their outcome risk?), prognostic models (can we predict an individual's risk using multiple prognostic factors?), and predictors of treatment effect (can we predict which treatments work best for individual patients?). Prognosis research findings allow health professionals to more accurately predict and therefore intervene to improve the health outcomes of individuals.Thousands of prognosis studies are published each year, and many have unclear or contradictory findings. This makes it difficult for healthcare professionals to know how best to use these findings to improve the care of their patients. This motivates the need for systematic reviews of prognosis studies. These aim to identify all existing prognosis studies on a particular topic, and to appraise their quality and, if appropriate, combine their results (using meta-analysis) to provide overall answers for healthcare professionals. Systematic review methods are well-established in other areas of medical research, but are only just emerging for prognosis research. In our project, we will develop and make freely available reliable methods to undertake systematic reviews of prognosis studies. We have named this initiative REVAMP, which stands for Systematic Reviews and Meta-Analysis of Prognosis Studies.We propose a series of five work projects (WPs) to be delivered by researchers with considerable expertise in prognosis research and systematic reviews. In WP1, we will develop and disseminate guidance for reviews of overall prognosis; which aim to provide a summary of the average risk in a particular population (e.g. those diagnosed with breast cancer). A step-by-step guide will be produced, covering aspects such as searching for relevant studies, data extraction, critical appraisal, and meta-analysis. Clear reporting is essential for those interpreting, critically appraising, and implementing prognosis research findings. However, no reporting guidelines currently exist for systematic reviews of prognosis studies. Therefore, in WP2 we will provide three reporting guidelines (checklists) for prognosis reviews: one for each of overall prognosis, prognostic factors and prognostic models. These will be developed through a consensus process involving researchers, healthcare professionals, organisations developing clinical guidelines, and patients.In WP3 and 5, we will develop new ways for researchers to calculate how many individuals are needed for a prognosis study. Current studies are often too small and so may have misleading results. We will use mathematical techniques to produce a new way to calculate sample size, so that it will be easier to judge (i) whether an existing prognostic model study was large enough to be fit-for-purpose, and (ii) what size a new prognosis study needs to be to contribute usefully to a future updated review. In WP4 we will produce step-by-step guidance for conducting reviews of predictors of treatment effect, particularly how to do critical appraisal and meta-analysis when the aim is to summarise whether a treatment's effect depends on patient characteristics such as age.Our project's findings will be disseminated in a Methodology Handbook for Prognosis Reviews and through a new UK-based research training course, in addition to publications in journals and via blogs and tutorial videos at websites including www.prognosisresearch.com.
医疗保健研究正处于一个令人兴奋的新阶段。研究人员现在可以获得大量信息,将个人特征(如年龄、家族史或遗传信息)与健康结果(如死亡、疼痛程度、抑郁评分)联系起来。研究人员正在利用这些信息来帮助卫生专业人员和患者了解和预测未来的结果。这样的研究被称为预后研究,包括四种类型:总体预后(人群中的平均结局风险是多少?)、预后因素(患者的哪些特征有助于了解其结局风险?)、预后模型(我们能否利用多种预后因素预测个体的风险?)和治疗效果预测因子(我们能否预测哪种治疗方法对个体患者最有效?)。预后研究结果使卫生专业人员能够更准确地预测并因此进行干预,以改善个人的健康结果。每年有成千上万的预后研究发表,其中许多研究结果不明确或相互矛盾。这使得医疗保健专业人员很难知道如何最好地利用这些发现来改善患者的护理。这激发了对预后研究进行系统回顾的需求。这些研究的目的是确定一个特定主题的所有现有预后研究,并评估其质量,如果合适,将其结果(使用荟萃分析)结合起来,为医疗保健专业人员提供总体答案。系统评价方法在其他医学研究领域已经建立,但在预后研究中才刚刚出现。在我们的项目中,我们将开发并免费提供可靠的方法来进行预后研究的系统审查。我们将这项计划命名为REVAMP,即预后研究的系统评价和荟萃分析。我们建议由在预后研究和系统评价方面具有相当专业知识的研究人员提供一系列五个工作项目(WPs)。在世卫组织第一阶段,我们将制定和传播评估总体预后的指南;其目的是提供特定人群(例如那些被诊断患有乳腺癌的人)的平均风险摘要。一份循序渐进的指南将会被制作出来,涵盖相关研究的搜索、数据提取、批判性评估和元分析等方面。清晰的报告对于那些解释、批判性评价和实施预后研究结果至关重要。然而,目前尚无预后研究系统综述的报告指南。因此,在WP2中,我们将为预后审查提供三份报告指南(核对表):总体预后、预后因素和预后模型各一份。这些将通过涉及研究人员、医疗保健专业人员、制定临床指南的组织和患者的共识过程来制定。在WP3和w5中,我们将为研究人员开发新的方法来计算预后研究需要多少个体。目前的研究往往规模太小,因此可能会产生误导性的结果。我们将使用数学技术产生一种计算样本量的新方法,以便更容易判断(i)现有的预后模型研究是否足够大以适合目的,以及(ii)新的预后研究需要多大的规模才能对未来更新的综述有用。在WP4中,我们将为治疗效果预测因素的评估提供逐步指导,特别是当目的是总结治疗效果是否取决于患者特征(如年龄)时,如何进行关键评估和荟萃分析。我们项目的研究结果将在《预后评估方法手册》中传播,并通过一个新的英国研究培训课程传播,此外还将在期刊上发表文章,并通过博客和www.prognosisresearch.com等网站上的教程视频传播。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard Riley其他文献

Journal Pre-proof Non-linear effects and effect modification at the participant-level in IPD meta-analysis part 2: Methodological guidance is available
期刊预校对 IPD 荟萃分析参与者层面的非线性效应和效应修改第 2 部分:提供方法学指导
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    N. Marlin;P. Godolphin;Richard Hooper;Richard Riley;E. Rogozińska
  • 通讯作者:
    E. Rogozińska
793: A new prediction model for birth within 48 hours in women with preterm labour symptoms
  • DOI:
    10.1016/j.ajog.2019.11.809
  • 发表时间:
    2020-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah J. Stock;Margaret Horne;Merel Bruijn;Rachel Morris;Jon Dorling;Lesley Jackson;Manju Chandiramani;Anna L. David;Asma Khalil;Andrew Shennan;Gert-Jan Van Baaren;Ewoud Schuit;Susan Harper-Clarke;Ben Mol;Richard Riley;Jane E. Norman;John Norrie
  • 通讯作者:
    John Norrie
Discontinued SEC required disclosures: The value of repairs and maintenance expenses
  • DOI:
    10.1016/j.racreg.2011.06.011
  • 发表时间:
    2011-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Bruce K. Behn;Richard Riley;Giorgio Gotti;Richard C. Brooks
  • 通讯作者:
    Richard C. Brooks
Monitoring for 5-aminosalicylate toxicity: prognostic model development and validation.
5-氨基水杨酸盐​​毒性监测:预后模型开发和验证。
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    G. Nakafero;M. Grainge;Tim Card;Maarten W. Taal;G. Aithal;Christopher P Fox;Christian D Mallen;Matthew D Stevenson;Richard Riley;Prof. Abhishek
  • 通讯作者:
    Prof. Abhishek
Reviewing the evidence supporting predictive biomarkers in European medicines agency indications and contraindications using visual plots
  • DOI:
    10.1186/1745-6215-16-s2-p157
  • 发表时间:
    2015-11-16
  • 期刊:
  • 影响因子:
    2.000
  • 作者:
    Kinga Malottki;Lucinda Billingham;Richard Riley;Jonathan Deeks
  • 通讯作者:
    Jonathan Deeks

Richard Riley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard Riley', 18)}}的其他基金

Sample Size calculations for UPDATing clinical prediction models to Ensure their accuracy and fairness in practice (SS-UPDATE)
用于更新临床预测模型的样本量计算,以确保其在实践中的准确性和公平性(SS-UPDATE)
  • 批准号:
    MR/Z503873/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Research Grant
Systematic Reviews and Meta-Analysis of Prognosis Studies (REVAMP): development of core methods, reporting guidelines and a methodology handbook
预后研究的系统评价和荟萃分析 (REVAMP):制定核心方法、报告指南和方法手册
  • 批准号:
    MR/V038168/1
  • 财政年份:
    2021
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Research Grant
Multivariate meta-analysis of multiple correlated outcomes: development and application of methods, with empirical investigation of clinical impact
多个相关结果的多变量荟萃分析:方法的开发和应用,以及临床影响的实证研究
  • 批准号:
    MR/J013595/2
  • 财政年份:
    2015
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Research Grant
Multivariate meta-analysis of multiple correlated outcomes: development and application of methods, with empirical investigation of clinical impact
多个相关结果的多变量荟萃分析:方法的开发和应用,以及临床影响的实证研究
  • 批准号:
    MR/J013595/1
  • 财政年份:
    2013
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Research Grant

相似海外基金

A Postdoctoral Fellowship in Systematic Reviews and Meta-Analyses
系统评价和荟萃分析博士后奖学金
  • 批准号:
    2329570
  • 财政年份:
    2023
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Standard Grant
Update of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extensions for network meta-analyses, rapid reviews, and scoping reviews
系统评价和荟萃分析首选报告项目 (PRISMA) 更新,用于网络荟萃分析、快速审核和范围界定审核
  • 批准号:
    478557
  • 财政年份:
    2023
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Operating Grants
Exploring and developing methods for meta-analyses in updated and living systematic reviews.
探索和开发更新和实时系统评价中的荟萃分析方法。
  • 批准号:
    475567
  • 财政年份:
    2022
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Studentship Programs
Systematic Reviews and Meta-Analysis of Prognosis Studies (REVAMP): development of core methods, reporting guidelines and a methodology handbook
预后研究的系统评价和荟萃分析 (REVAMP):制定核心方法、报告指南和方法手册
  • 批准号:
    MR/V038168/1
  • 财政年份:
    2021
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Research Grant
Assessment of the current state of the consideration of specific features of time-to-event analyses in meta-analyses: re-analysis of systematic reviews and implementation of guidance
评估荟萃分析中考虑事件时间分析具体特征的现状:系统评价的重新分析和指南的实施
  • 批准号:
    437030575
  • 财政年份:
    2020
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Research Grants
Investigating human influences in systematic reviews and meta-analyses to improve the reliability and validity of evidence syntheses
在系统评价和荟萃分析中研究人类影响,以提高证据合成的可靠性和有效性
  • 批准号:
    MR/T009861/1
  • 财政年份:
    2020
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Fellowship
Clinical predictive value of systematic reviews with meta-analysis for future research on patients with multiple chronic conditions: a demonstration project using the case of preventive statin therapy
系统评价与荟萃分析对多种慢性病患者未来研究的临床预测价值:使用预防性他汀类药物治疗案例的示范项目
  • 批准号:
    9224036
  • 财政年份:
    2016
  • 资助金额:
    $ 47.74万
  • 项目类别:
Systematic Reviews with Network Meta-Analyses to Compare Interventions for Sudden Hearing Loss, Single Sided Deafness and Meniere's Disease
通过网络荟萃分析进行系统评价,比较突发性听力损失、单侧耳聋和梅尼埃病的干预措施
  • 批准号:
    357172
  • 财政年份:
    2016
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Operating Grants
Development and implementation of a reporting guideline for systematic reviews and meta-analyses of diagnostic accuracy studies: The PRISMA-DTA initiative
制定和实施诊断准确性研究的系统评价和荟萃分析报告指南:PRISMA-DTA 计划
  • 批准号:
    355624
  • 财政年份:
    2016
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Operating Grants
Relation of different food sources of sugars with incident cardiometabolic disease: A series of systematic reviews and meta-analyses to inform guidelines, public health policy, and future research design
不同食物来源的糖与心脏代谢疾病的关系:一系列系统评价和荟萃分析,为指南、公共卫生政策和未来研究设计提供信息
  • 批准号:
    331017
  • 财政年份:
    2015
  • 资助金额:
    $ 47.74万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了